Mining stocks listed on the FTSE 250 index posted strong gains in the latest trading session, leading the mid-cap index higher amid a broadly positive market mood.
The performance of mining companies reflected renewed investor appetite for commodities, as global demand signals continued to support the sector.
Base metals have attracted fresh buying interest in recent months, with mid-cap miners benefiting from firmer pricing across several key industrial materials.
The FTSE 250, which tracks the 101st to the 350th largest companies listed in London, is often seen as a reliable barometer of domestic and internationally exposed UK business sentiment.
While miners were among the standout performers, the session was marked by a sharp contrast with Oxford Biomedica, whose shares fell sharply and weighed on the index.
Oxford Biomedica, a cell and gene therapy contract development and manufacturing organisation, has faced a difficult period as investor confidence in the biotech sector remains fragile.
The company operates in a highly specialised and capital-intensive space, where clinical timelines, partnership developments, and regulatory milestones can all move share prices significantly.
Broader biotech and life sciences stocks have struggled to regain momentum, with institutional investors remaining cautious about near-term profitability in the sector.
The divergence between mining stocks and healthcare or biotech names reflects a wider rotation in markets, with investors favouring hard assets and commodity exposure over growth-oriented sectors.
Commodity-linked equities have broadly outperformed early in 2026, as supply constraints and industrial demand from key markets continue to underpin prices.
Traders noted that sector rotation has been a dominant theme across UK equity markets this year, with defensives and resource stocks drawing the most attention.
The FTSE 250 as a whole has seen intermittent volatility, though pockets of strength in energy and materials have helped cushion broader market uncertainty.
Oxford Biomedica’s share price decline serves as a reminder of the risks inherent in contract biomanufacturing businesses, where client pipelines and deal flow are critical to revenue visibility.
Investors will be watching upcoming trading updates and any partnership announcements closely to gauge whether sentiment around the stock can stabilise.